New triple therapy shows promise for Tough-to-Treat lung cancer
NCT ID NCT04340882
First seen Nov 05, 2025 · Last updated Jun 11, 2026 · Updated 25 times
Summary
This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current options to control the cancer. Participants must have already tried platinum-based chemo and an immunotherapy drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Grady Health System
Atlanta, Georgia, 30303, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.